Hemispherx BioPharma (HEB) Shares are Down -3.59%

Hemispherx BioPharma (HEB) has risen sharply, recording gains of 47.86% in the past 4 weeks. However, the stock has corrected -3.59% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 46.35% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.

The stock has recorded a 20-day Moving Average of 24.31% and the 50-Day Moving Average is 38.89%. Hemispherx BioPharma (NYSEMKT:HEB): stock turned positive on Friday. Though the stock opened at $0.18, the bulls momentum made the stock top out at $0.1841 level for the day. The stock recorded a low of $0.1641 and closed the trading day at $0.1798, in the green by 1.99%. The total traded volume for the day was 862,977. The stock had closed at $0.1763 in the previous days trading.


The company Insiders own 5.85% of Hemispherx BioPharma shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by 14.75% . Institutional Investors own 6.1% of Hemispherx BioPharma shares.

Hemispherx Biopharma, Inc. (Hemispherx) is a specialty pharmaceutical company engaged in the clinical development of new drugs therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The Companys flagship products include Alferon N Injection and Ampligen. Alferon N Injection is approved for the use in intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older. Ampligen is an experimental drug undergoing clinical development for the treatment of CFS (Chronic Fatigue Syndrome). The Companys Alferon LDO (Low Dose Oral) is an experimental liquid natural interferon for oral administration.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.